Tonix Pharmaceuticals Holding Corp.(TNXP)Earnings, Financials & Key Ratios
TNXP•NASDAQ
$14.69
$33M mkt cap·Price updated May 6, 2026
AboutTonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.Show more
- Revenue$10M+29.9%
- EBITDA-$133M-16.8%
- Net Income-$130M-11.5%
- EPS (Diluted)-176.60+97.2%
- Gross Margin23.07%-40.8%
- EBITDA Margin-1320.39%+10.1%
- Operating Margin-1354.28%+11.1%
- Net Margin-1288.25%+14.2%
- ROE-106.12%-42.2%
- ROIC-150.25%-50.7%
- Debt/Equity0.04-59.2%
TNXP Key Insights
Tonix Pharmaceuticals Holding Corp. (TNXP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.2x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 17 (bottom 17%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 23.6% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TNXP Price & Volume
Tonix Pharmaceuticals Holding Corp. (TNXP) stock price & volume — 10-year historical chart
Loading chart...
TNXP Growth Metrics
Tonix Pharmaceuticals Holding Corp. (TNXP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-8.79%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM26.64%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM99.77%
Return on Capital
10 Years-99.53%
5 Years-76.5%
3 Years-73.05%
Last Year-97.59%
TNXP Peer Comparison
Tonix Pharmaceuticals Holding Corp. (TNXP) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AXSM | 11.46B | 222.63 | -60.50 | 65.55% | -26.59% | -260.01% | 2.73 | |
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 SUPN | 2.96B | 51.45 | -75.66 | 8.63% | -3.74% | -2.73% | 0.04 | |
 CORT | 5.6B | 52.15 | 63.60 | 12.79% | 6.23% | 7.5% | 0.01 | |
 PCRX | 931.85M | 23.69 | 148.06 | 3.63% | 1.27% | 1.31% | 0.66 | |
 JAZZ | 14.34B | 228.57 | -39.14 | 4.88% | 0.66% | 0.71% | 1.26 | |
 AVPT | 2.22B | 10.27 | 68.47 | 26.93% | 8.3% | 7.95% | 0.02 | |
 PTCT | 5.52B | 66.61 | 8.56 | 114.51% | 39.44% |
Compare TNXP vs Peers
Tonix Pharmaceuticals Holding Corp. (TNXP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TNXP Income Statement
Tonix Pharmaceuticals Holding Corp. (TNXP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.77M | 10.09M | 10.3M |
| Revenue Growth % | - | - | - | - | - | - | - | - | 29.94% | -8.79% |
| Cost of Goods Sold | 38.97M | 21.29M | 26.32M | 0 | 27K | 0 | 0 | 4.74M | 7.76M | 6.76M |
| COGS % of Revenue | - | - | - | - | - | - | - | 61.03% | 76.93% | - |
| Gross Profit | -38.97M▲ 0% | -21.29M▲ 45.4% | -26.32M▼ 23.6% | 0▲ 100.0% | -27K▲ 0% | 0▲ 100.0% | 0▲ 0% | 3.03M▲ 0% | 2.33M▼ 23.1% | 3.53M▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | 38.97% | 23.07% | 34.31% |
| Gross Profit Growth % | 19.09% | 45.36% | -23.63% | 100% | - | 100% | - | - | -23.06% | - |
| Operating Expenses | 38.97M | 21.29M | 26.32M | 28.83M | 50.48M | 92.31M | 112.09M | 121.41M | 139.03M | 103.43M |
| OpEx % of Revenue | - | - | - | - | - | - | - | 1562.91% | 1377.35% | - |
| Selling, General & Admin | 10.44M | 7.95M | 8.76M | 10.64M | 14.33M | 23.47M | 30.21M | 34.75M | 40.1M | 25.69M |
| SG&A % of Revenue | - | - | - | - | - | - | - | 447.37% | 397.28% | - |
| Research & Development | 28.53M | 13.34M | 17.56M | 18.19M | 36.16M | 68.84M | 81.88M | 86.66M | 40.45M | 35.84M |
| R&D % of Revenue | - | - | - | - | - | - | - | 1115.54% | 400.71% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 58.48M | 2M |
| Operating Income | -38.97M▲ 0% | -21.29M▲ 45.4% | -26.32M▼ 23.6% | -28.83M▼ 9.5% | -50.51M▼ 75.2% | -92.31M▼ 82.8% | -112.09M▼ 21.4% | -118.38M▼ 5.6% | -136.7M▼ 15.5% | -99.9M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | -1523.94% | -1354.28% | -969.97% |
| Operating Income Growth % | 19.09% | 45.36% | -23.63% | -9.52% | -75.22% | -82.76% | -21.43% | -5.61% | -15.48% | - |
| EBITDA | -38.76M | -21.23M | -26.27M | -28.8M | -50.48M | -92.26M | -110.84M | -114.09M | -133.28M | -97.96M |
| EBITDA Margin % | - | - | - | - | - | - | - | -1468.7% | -1320.39% | -951.2% |
| EBITDA Growth % | 19.25% | 45.24% | -23.75% | -9.65% | -75.28% | -82.75% | -20.13% | -2.93% | -16.82% | -25.31% |
| D&A (Non-Cash Add-back) | 206K | 64K | 54K | 26K | 27K | 50K | 1.25M | 4.29M | 3.42M | 1.93M |
| EBIT | -38.97M | -21.29M | -26.32M | -28.83M | -50.46M | -92.31M | -112.09M | -118.38M | -77.74M | -99.24M |
| Net Interest Income | 0 | 0 | 0 | 0 | 48K | 25K | 1.87M | 0 | 0 | 2.17M |
| Interest Income | 127K | 168K | 233K | 0 | 48K | 25K | 1.87M | 0 | 0 | 2.17M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 127K | 168K | 233K | 210K | 48K | 25K | 1.87M | 1.72M | 6.67M | 678K |
| Pretax Income | -38.84M▲ 0% | -21.12M▲ 45.6% | -26.09M▼ 23.5% | -28.62M▼ 9.7% | -50.46M▼ 76.3% | -92.29M▼ 82.9% | -110.22M▼ 19.4% | -116.66M▼ 5.8% | -130.04M▼ 11.5% | -99.22M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | -1501.78% | -1288.25% | -963.38% |
| Income Tax | -206K | -70K | 233K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.53% | 0.33% | -0.89% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -38.84M▲ 0% | -21.12M▲ 45.6% | -29.36M▼ 39.0% | -28.62M▲ 2.5% | -50.46M▼ 76.3% | -92.29M▼ 82.9% | -110.22M▼ 19.4% | -116.66M▼ 5.8% | -130.04M▼ 11.5% | -99.22M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | -1501.78% | -1288.25% | -963.38% |
| Net Income Growth % | 19.17% | 45.62% | -38.97% | 2.51% | -76.33% | -82.88% | -19.43% | -5.84% | -11.47% | 26.64% |
| Net Income (Continuing) | -38.84M | -21.12M | -26.09M | -28.62M | -50.46M | -92.29M | -110.22M | -116.66M | -130.04M | -99.22M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -199189.74▲ 0% | -54023.02▲ 72.9% | -18064.62▲ 66.6% | -3866.00▲ 78.6% | -5056.00▼ 30.8% | -163968.00▼ 3143.0% | -811.68▲ 99.5% | -6368.84▼ 684.6% | -176.60▲ 97.2% | -11.12▲ 0% |
| EPS Growth % | 61.04% | 72.88% | 66.56% | 78.6% | -30.78% | -3143.04% | 99.5% | -684.65% | 97.23% | 99.77% |
| EPS (Basic) | -199189.74 | -54023.02 | -18064.62 | -3866.00 | -5056.00 | -163968.00 | -811.68 | -6368.84 | -176.60 | - |
| Diluted Shares Outstanding | 19.5K | 39.1K | 162.5K | 804.2K | 2.56M | 563 | 3.07M | 1.83M | 2.26M | 8.92M |
| Basic Shares Outstanding | 19.5K | 39.1K | 162.5K | 804.2K | 2.56M | 563 | 3.07M | 1.83M | 2.26M | 8.92M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
TNXP Balance Sheet
Tonix Pharmaceuticals Holding Corp. (TNXP) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 27.14M | 26.44M | 26.06M | 13.95M | 87.99M | 189.05M | 130.78M | 47.77M | 119M | 208.07M |
| Cash & Short-Term Investments | 26.12M | 25.5M | 25.03M | 11.25M | 77.07M | 178.66M | 120.23M | 24.95M | 98.78M | 190.06M |
| Cash Only | 18.94M | 25.5M | 25.03M | 11.25M | 77.07M | 178.66M | 120.23M | 24.95M | 98.78M | 190.06M |
| Short-Term Investments | 7.18M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 525K | 1.01M | 7.63M | 7.73M | 8.04M | 4.59M | 7.9M | 3.48M |
| Days Sales Outstanding | - | - | - | - | - | - | - | 215.67 | 285.81 | 213.39 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14.15M | 8.41M | 5.73M |
| Days Inventory Outstanding | - | - | - | - | - | - | - | 1.09K | 395.22 | 381.17 |
| Other Current Assets | 0 | 0 | 497K | 400K | 1.66M | 1.18M | 1.23M | 2.43M | 1.46M | 8.81M |
| Total Non-Current Assets | 370K | 311K | 263K | 610K | 10.19M | 51.85M | 94.91M | 106.69M | 43.89M | 44.37M |
| Property, Plant & Equipment | 150K | 91K | 43K | 390K | 9.83M | 51.47M | 94.53M | 94.85M | 42.82M | 42.95M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | 0.08x | 0.24x | 0.24x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 965K | 0 | 0 |
| Intangible Assets | 120K | 120K | 120K | 0 | 120K | 120K | 120K | 9.74M | 120K | 120K |
| Long-Term Investments | 89K | 89K | 100K | 0 | 240K | 240K | 0 | 0 | 904K | 2.71M |
| Other Non-Current Assets | 100K | 100K | 100K | 100K | 245K | 259K | 264K | 1.13M | 47K | 1.38M |
| Total Assets | 27.51M▲ 0% | 26.75M▼ 2.7% | 26.32M▼ 1.6% | 14.56M▼ 44.7% | 98.18M▲ 574.4% | 240.9M▲ 145.4% | 225.69M▼ 6.3% | 154.46M▼ 31.6% | 162.89M▲ 5.5% | 252.44M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | 0.05x | 0.06x | 0.05x |
| Asset Growth % | -41.49% | -2.75% | -1.63% | -44.69% | 574.43% | 145.36% | -6.31% | -31.56% | 5.46% | 380.21% |
| Total Current Liabilities | 2.12M | 2.13M | 2.65M | 5.13M | 9.82M | 21.72M | 18.18M | 18.88M | 18.31M | 21.03M |
| Accounts Payable | 872K | 1.3M | 1.4M | 3.07M | 4.6M | 13.28M | 8.07M | 3.78M | 4.55M | 8.54M |
| Days Payables Outstanding | 8.17 | 22.22 | 19.47 | - | 62.16K | - | - | 291.17 | 213.69 | 338.05 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.35M | 0 | 159K |
| Deferred Revenue (Current) | 504K | 519K | 475K | 704K | 2.17M | 2.83M | 3.27M | 2.98M | 1.82M | 6.76M |
| Other Current Liabilities | 0 | 0 | 0 | 690K | 452K | 2.25M | 3.65M | 5.14M | 7.32M | 12.33M |
| Current Ratio | 12.83x | 12.44x | 9.81x | 2.72x | 8.96x | 8.71x | 7.19x | 2.53x | 6.50x | 6.50x |
| Quick Ratio | 12.83x | 12.44x | 9.81x | 2.72x | 8.96x | 8.71x | 7.19x | 1.78x | 6.04x | 6.04x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | 1.01K | 467.35 | 256.51 |
| Total Non-Current Liabilities | 33K | 12K | 0 | 6K | 716K | 467K | 328K | 30.05M | 5.03M | 266K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.56M | 4.67M | 266K |
| Capital Lease Obligations | 0 | 0 | 0 | 6K | 716K | 467K | 328K | 632K | 358K | 983K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 22.86M | 0 | 0 |
| Total Liabilities | 2.15M | 2.14M | 2.65M | 5.14M | 10.54M | 22.18M | 18.51M | 48.93M | 23.33M | 21.3M |
| Total Debt | 0 | 0 | 0 | 358K | 1.31M | 956K | 760K | 9.81M | 5.3M | 425K |
| Net Debt | -18.94M | -25.5M | -25.03M | -10.89M | -75.76M | -177.7M | -119.47M | -15.13M | -93.48M | -189.63M |
| Debt / Equity | - | - | - | 0.04x | 0.01x | 0.00x | 0.00x | 0.09x | 0.04x | 0.04x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.94x |
| Interest Coverage | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 25.36M▲ 0% | 24.62M▼ 2.9% | 23.66M▼ 3.9% | 9.42M▼ 60.2% | 87.65M▲ 830.7% | 218.72M▲ 149.5% | 207.18M▼ 5.3% | 105.53M▼ 49.1% | 139.56M▲ 32.3% | 231.14M▲ 0% |
| Equity Growth % | -37.01% | -2.94% | -3.87% | -60.21% | 830.74% | 149.54% | -5.27% | -49.07% | 32.25% | 609.55% |
| Book Value per Share | 1300.56 | 629.57 | 145.62 | 11.71 | 34.23 | 388597.79 | 67.51 | 57.61 | 61.66 | 25.90 |
| Total Shareholders' Equity | 25.36M | 24.62M | 23.66M | 9.42M | 87.65M | 218.72M | 207.18M | 105.53M | 139.56M | 231.14M |
| Common Stock | 4K | 8K | 3K | 9K | 206K | 496K | 12K | 59K | 4K | 10K |
| Retained Earnings | -141.24M | -162.36M | -188.45M | -217.07M | -267.53M | -359.82M | -470.04M | -600.66M | -730.69M | -807.8M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -7K | -12K | -41K | -46K | -62K | -92K | -167K | -232K | -255K | -274K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TNXP Cash Flow Statement
Tonix Pharmaceuticals Holding Corp. (TNXP) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -37.31M | -19.13M | -23.97M | -26.68M | -48.57M | -75.56M | -98.05M | -102M | -60.92M | -60.92M |
| Operating CF Margin % | - | - | - | - | - | - | - | -1313.12% | -603.58% | - |
| Operating CF Growth % | 12.26% | 48.74% | -25.32% | -11.31% | -82.01% | -55.58% | -29.77% | -4.03% | 40.27% | -62.45% |
| Net Income | -38.84M | -21.12M | -26.09M | -28.62M | -50.46M | -92.29M | -110.22M | -116.66M | -130.04M | -99.22M |
| Depreciation & Amortization | 206K | 70K | 54K | 26K | 27K | 50K | 1.25M | 4.29M | 3.42M | 1.93M |
| Stock-Based Compensation | 3.27M | 1.79M | 1.63M | 1.46M | 2.88M | 7.9M | 10.91M | 9.28M | 4.78M | 5M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 133K | 1.5M | 1.63M | 0 | 1.36M | 3M | 0 | 1.12M | 55.14M | 7.32M |
| Working Capital Changes | -2.08M | 135K | 437K | 452K | -2.37M | 5.78M | -2K | -35K | 5.78M | 10.14M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3.68M | 1.47M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 61K | 3.74M | 1.41M |
| Change in Payables | -2.19M | 424K | 106K | 1.66M | 1.53M | 3.53M | -1.04M | -3.49M | 927K | 3.29M |
| Cash from Investing | 16.59M | 7.17M | -6K | -17K | -8.56M | -35.31M | -48.15M | -29.07M | -120K | -3.51M |
| Capital Expenditures | -66K | -5K | -6K | -17K | -8.56M | -35.31M | -48.15M | -7.89M | -120K | -1.5M |
| CapEx % of Revenue | - | - | - | - | - | - | - | 101.63% | 1.19% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -22.17M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 45K | 7.17M | -6K | 0 | 0 | 0 | 0 | 999K | 0 | -2.01M |
| Cash from Financing | 20.5M | 18.52M | 23.54M | 12.92M | 123.11M | 212.49M | 87.84M | 36.52M | 134.87M | 240.54M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.94M | -2.35M | -10.36M |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 3M |
| Dividends Paid | 0 | 0 | -3.27M | 0 | -451K | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -13.96M | 0 | -5.95M |
| Other Financing | 0 | 14K | 3.27M | 101K | 10.35M | 98K | 40K | 22.6M | -2.97M | 95.2M |
| Net Change in Cash | -234K▲ 0% | 6.55M▲ 2901.3% | -451K▼ 106.9% | -13.79M▼ 2956.5% | 65.96M▲ 578.5% | 101.59M▲ 54.0% | -58.43M▼ 157.5% | -94.62M▼ 61.9% | 73.83M▲ 178.0% | 162.21M▲ 0% |
| Free Cash Flow | -37.38M▲ 0% | -19.13M▲ 48.8% | -23.98M▼ 25.3% | -26.7M▼ 11.4% | -57.13M▼ 114.0% | -110.86M▼ 94.1% | -146.2M▼ 31.9% | -109.9M▲ 24.8% | -61.05M▲ 44.5% | -78.33M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | -1414.75% | -604.77% | -760.6% |
| FCF Growth % | 12.59% | 48.82% | -25.32% | -11.36% | -113.97% | -94.06% | -31.87% | 24.83% | 44.45% | -13.22% |
| FCF per Share | -1916.97 | -489.34 | -147.55 | -33.20 | -22.31 | -196973.74 | -47.64 | -60.00 | -26.97 | -26.97 |
| FCF Conversion (FCF/Net Income) | 0.96x | 0.91x | 0.82x | 0.93x | 0.96x | 0.82x | 0.89x | 0.87x | 0.47x | 0.79x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 88K | 1.23M | 369K |
| Taxes Paid | 0 | 65K | 82K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TNXP Key Ratios
Tonix Pharmaceuticals Holding Corp. (TNXP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -118.38% | -84.53% | -121.6% | -173.02% | -103.98% | -60.25% | -51.76% | -74.61% | -106.12% | -42.93% |
| Return on Invested Capital (ROIC) | -212.5% | -576.47% | - | - | -727.34% | -261.73% | -130.62% | -99.7% | -150.25% | -150.25% |
| Gross Margin | - | - | - | - | - | - | - | 38.97% | 23.07% | 34.31% |
| Net Margin | - | - | - | - | - | - | - | -1501.78% | -1288.25% | -963.38% |
| Debt / Equity | - | - | - | 0.04x | 0.01x | 0.00x | 0.00x | 0.09x | 0.04x | 0.04x |
| FCF Conversion | 0.96x | 0.91x | 0.82x | 0.93x | 0.96x | 0.82x | 0.89x | 0.87x | 0.47x | 0.79x |
| Revenue Growth | - | - | - | - | - | - | - | - | 29.94% | -8.79% |
TNXP Frequently Asked Questions
Tonix Pharmaceuticals Holding Corp. (TNXP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Tonix Pharmaceuticals Holding Corp. (TNXP) reported $10.3M in revenue for fiscal year 2024.
Tonix Pharmaceuticals Holding Corp. (TNXP) grew revenue by 29.9% over the past year. This is strong growth.
Tonix Pharmaceuticals Holding Corp. (TNXP) reported a net loss of $99.2M for fiscal year 2024.
Dividend & Returns
Tonix Pharmaceuticals Holding Corp. (TNXP) has a return on equity (ROE) of -106.1%. Negative ROE indicates the company is unprofitable.
Tonix Pharmaceuticals Holding Corp. (TNXP) had negative free cash flow of $78.3M in fiscal year 2024, likely due to heavy capital investments.
Explore More TNXP
Tonix Pharmaceuticals Holding Corp. (TNXP) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates